Treating hepatitis C viral infection in patients with chronic kidney disease: When and how

Pedraza, Fernando; Avellaneda, M.; Roth, David

doi:10.1002/cld.617

Cited by 3 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also can be administered to HCV patients with chronic kidney disease. 3 In Indonesia, currently there were no studies that describe the effect of DAA regiment on glomerular filtration rate, therefore this study was conducted to determine the effect of DAA regiment on glomerular filtration rate in hepatitis C patients.…”

Section: Introductionmentioning

confidence: 99%

Association Between Glomerular Filtration Rate and Direct-Acting Antiviral Regiment in Chronic Hepatitis C: A Retrospective Cohort Study

Lindriawaty¹,

Daud²,

Kasim³

et al. 2020

Int Res J Pharm

View full text Add to dashboard Cite

Treatment of hepatitis C virus (HCV) infection is currently developing, but some antiviral agents are reported to cause kidney dysfunction. Currently, direct-acting antivirals (DAA) are the best choice in the management of HCV infection with high efficacy, minimal side effects and better tolerability. This study was conducted to evaluate the glomerular filtration rate (GFR) given DAA regiment outcome in hepatitis C patients. An observational analytic study, with a prospective cohort design, was conducted at Wahidin Sudirohusodo Hospital. Subjects included were patients diagnosed with HCV infection and treated with DAA. Patients with hepatitis B or human immunodeficiency virus co-infection or have chronic kidney disease were excluded. Serum creatinine was evaluated before and after observational period; 12 weeks in non-cirrhosis and 24 weeks in cirrhosis patients. Independent t-test, Paired t-test, and Chi-square were used for statistical analysis of the data. A total of 50 subjects were evaluated, 25 subjects (50 %) included to the sofosbuvir-simeprevir regiment group, 22 subjects (44 %) in sofosbuvir-daclatasvir regiment group and 3 subjects (6 %) in sofosbuvirribavirin regiment group. There is no association between 12 weeks or 24 weeks of treatment period with GFR in pre-and post-DAA treatment (p-value > 0.05). There is no association between the type of DAA combination regiment with GFR in pre-and post-DAA treatment (p-value > 0.05). There is no association between DAA characteristic based on the duration of treatment and regiment of DAA with glomerular filtration rate in chronic hepatitis C patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Association Between Glomerular Filtration Rate and Direct-Acting Antiviral Regiment in Chronic Hepatitis C: A Retrospective Cohort Study

Lindriawaty¹,

Daud²,

Kasim³

et al. 2020

Int Res J Pharm

View full text Add to dashboard Cite

show abstract

Adjuvant Use of Ribavirin With Treatment of Hepatitis C Virus in Kidney Transplant Recipients

Tiwari

Bashir²,

Verma³

et al. 2022

Indian Journal of Transplantation

View full text Add to dashboard Cite

Hepatitis C virus infection among kidney transplant recipients (KTRs) is an important public health concern worldwide. Evidence on available treatments given shows a greater variability for safety and efficacy, thus we performed this large analysis to present the pooled findings. PubMed/Medline, ScienceDirect, and Google Scholar were searched to identify observational studies of both interferon-based conventional treatment (CT) and recently approved direct-acting antivirals (DAAs), published before November 2020. Meta-analysis of effectiveness outcome (sustained virological response [SVR12]) and safety data (adverse events and discontinuation rate) was performed using a random-effect model. Subgroup analysis based on ± ribavirin with both treatments was performed to assess its relevance in clinical practice. Chi-square and I 2 tests were used to assess heterogeneity between the studies. Twenty-five and 9 observational records reporting on treatment with DAAs (n = 943) and CT (n = 125), respectively, are analyzed. The overall pooled estimate of SVR12 rate was found as 95.3%, (range: 92.6%–97%) with DAAs in comparison to 46.4% (range: 33.7%–59.6%) with CT. The pooled prevalence of adverse drug reactions (ADRs) in CT was higher as 47.8% than in DAAs as 23.8%, consequently showing a high discontinuation rate of 31.7% in CT as compared to 6.5% with DAAs. Subgroup analyses of both DAAs and interferon-based treatment ± ribavirin showed decreased effectiveness and increased ADR rates on adding ribavirin. The effectiveness of DDAs was found significantly higher than CT with a better safety profile in KTRs. Ribavirin did not provide any additional benefits while given in combination with either of the treatments available.

show abstract

Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection

Danış

Töz

Ünal

et al. 2019

Turk J Gastroenterol

View full text Add to dashboard Cite

Treating hepatitis C viral infection in patients with chronic kidney disease: When and how

Abstract: http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/9-3-reading-pedraza.html a video presentation of this article http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/9-3-interview-roth.html the interview with the author

Cited by 3 publications

References 28 publications

Association Between Glomerular Filtration Rate and Direct-Acting Antiviral Regiment in Chronic Hepatitis C: A Retrospective Cohort Study

Association Between Glomerular Filtration Rate and Direct-Acting Antiviral Regiment in Chronic Hepatitis C: A Retrospective Cohort Study

Adjuvant Use of Ribavirin With Treatment of Hepatitis C Virus in Kidney Transplant Recipients

Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection

Contact Info

Product

Resources

About